A private equity investment firm based in Israel seeks early stage companies to form and establish, as well as investing to bridge the gap between late stage companies in Israel and companies with sales activity in the U.S. and Europe (“platforms”). The firm currently has a $130M fund that the firm is both allocating out of and raising with an aim of $300M. For early-stage companies, the firm typically invests from a few $100K to a couple million per company; for platforms/late stage, the firm usually invest up to $25M per company; and may syndicate for more capital if required. The firm invests in two platform deals and one early-stage company per year. The firm is interested in companies based in the U.S., Europe, or Israel.

The firm is interested in medical devices only. The firm is agnostic to disease indication and is not interested in pharmaceuticals. The firm may be interested in the diagnostics and digital health space, though is quite selective in these opportunities. For early-stage opportunities, the firm is interested in disruptive technologies at IP and/or preclinical stage. In the past, the firm has invested in diabetes, obesity, heart failure, structural heart, pulmonary hypertension, currently looking at neurology and urology, and is open to new areas of focus. For late-stage/Platform companies, the firm is interested in those that have sales between $30-70M as well as sales organization in different fields within the company’s space.

For early stage investment, the firm does not have a management team requirement, as it has the capability to invest in technology and IP alone and build the team around it. The firm is very active post investment by taking more than just a board seat, the firm gets very involved in the company formation and development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A new $125M life sciences venture fund affiliated with a leading research university is focused on early-stage healthcare technology in seed, Series A/B rounds. The firm is opportunistic geographically, though has preference for companies based in the USA.

The firm is interested in therapeutics, medical devices, and healthcare IT. The firm is opportunistic with particular interest in neuroscience, oncology, osteopathy, and ophthalmology products. In healthcare IT, the firm is interested in AI and augmented reality in life sciences. The firm seeks preclinical to clinical stage products.

The firm does not have a specific management team requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established venture capital firm is dedicated to funding private, early stage, pre-clinical and clinical neuroscience therapeutics and technologies for neurological and psychiatric diseases and disorders. The firm invests in Seed and Series A rounds, typically allocating $1-10 million USD for each deal. The firm looks for deals globally and plans to make 8-10 investments in the upcoming year. The firm is willing to lead rounds or co-invest as long as the investment falls within their investment criteria.

The firm is interested in devices, digital health, therapeutics, and diagnostics companies that focus on treating those with psychiatric and neurological diseases. The firm prefers technologies and therapeutics that are disease modifying and/or gain significant traction in disease symptom reduction. Technologies that improve quality of life or treatment delivery in neurological and psychiatric patient populations will also be considered. The firm is primarily interested in therapeutics and technologies that are pre-clinical or in development.

The firm sometimes prefers to take a board seat in companies in which they invest and prefers management teams that have a strong technical background within the clinical neuroscience area of focus.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global medical corporation headquartered in the USA is interested in making acquisitions and distribution agreements in the medical device sector, and does not invest in equity financing rounds. The firm typically makes 6-12 deals per year, including both early stage and mature companies. The firm will consider medical device opportunities worldwide.

The firm is interested in novel medical devices that fit into their existing clinical areas: anesthesia, respiratory devices, venous access, interventional devices (primarily in cardiology), surgical devices (with a focus on minimally invasive access and closure), urology, and OEM. In general, the firm prefers that products already have regulatory approval, but this is not an absolute requirement. The firm mostly focuses on devices that use a 510k pathway.

The firm focuses on products that have strong IP portfolios, good gross margins (65% or over) and which have the potential to really occupy an important market position. The firm has a global presence and therefore focuses on acquisitions and global rights rather than regional distribution.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based venture capital company founded in 2005 manages just under $50 million in assets across 2 funds and makes equity investments into companies ranging from a few hundred thousand dollars to $2million with additional capital reserved for follow on rounds. The firm is looking for companies located throughout the United States and plans to make 4 new investments over the next 6-9 months.

The firm is looking for companies developing Healthcare IT products, Life Science Research Tools and Medical Devices with an emphasis on fast to market low capital intense products that reduce the cost of delivering quality healthcare. For Healthcare IT investments the firm is most interested in machine learning and artificial intelligence (AI) applications and is generally not interested in Telehealth and EMR solutions. The firm is open to all sub-sectors and indications in the Medical technology space except for those targeting diseases and disorders of the spine. The firm will invest in both seed and later stage companies.

The firm is looking for companies with skilled and experienced management teams. The firm generally looks to take a board seat into companies after investment and play and active role in the management. The firm is willing to invest in both public and privately held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in Germany and Switzerland specializes in early-stage and growth capital investments in the Technology and Life Sciences sectors. The firm has approximately €1Bn AUM and is currently investing out of a €150M fund dedicated to the Life Sciences. Depending on the stage of the company, the firm can allocate up to €15M over the life of the investment. The firm can also lead or co-lead financing rounds of up to €30M or higher with syndication. The firm focuses on European companies but will consider US-based companies with activities in Europe. The firm is actively seeking new investment opportunities.

In the life sciences sector, the firm invests in therapeutics, medical technology, diagnostics, and digital medicine, and is opportunistic in terms of subsectors and indications. In therapeutics, the firm mainly focuses on early-stage companies with preclinical proof of concept data or about to enter the clinic, with a preference for companies developing highly innovative technology platforms. In diagnostics and medtech, the firm prefers companies with product candidates (with strong IP protection) approaching regulatory approval or companies who have already launched a first product. In digital medicine, the firm looks for data-driven technologies being applied clinically to drive meaningful change in patient outcomes.

The firm typically requests a board seat and looks for a strong and experienced management team, but will also support highly talented fledgling entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life science investment arm of a global private equity firm with $24 billion in assets under management may invest a total of up to $20 million per portfolio company across multiple financing rounds, and may be a lead investor or a co-investor. The firm is interested in life science opportunities worldwide. In addition to making equity investments from the life science investment arm, the firm also has another fund that invests in early growth companies in the medical device, healthcare IT and diagnostics sectors.

The life science investment arm invests in therapeutics, medical devices and diagnostics. For therapeutic investments, the fund generally looks for clinical proof of efficacy in Phase Ib or IIa trials. For PMA medical devices, the arm also requires clinical proof of efficacy data. For 510k devices and diagnostics, the arm makes growth equity investments in companies that have approved products and are in early commercialization. It is required that diagnostics have reimbursement codes. The arm will consider investments in any indication or technology area.

The growth investment arm invests in digital health, medtech and diagnostics companies with revenue streams, and uses a variety of structures to provide credit or royalty financing to early growth stage companies.

The firm invests in both experienced management teams, as well as new entrepreneurs. The firm is open to investing in both privately-held and public companies. If a management team is incomplete or inexperienced, the firm is open to working to fill or change the team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.